Granules India Ltd today said its US subsidiary has launched the generic version ofMethergine (Methylergonovine Maleate)tablets, in partnership with West-Ward Pharmaceuticals Corp, a wholly-owned subsidiary ofHikma Pharmaceuticals PLC.
Methylergonovine is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum haemorrhage.
A press release issued by Granules said this is the first product that the company has commercialized from its R&D and manufacturing facility in Virginia.
"We are happy to have collaborated with Hikma. Apart from the fact that Hikma has a proven history of being a responsible player in the market, we look at this launch as the inception towards building a strategic relationship."
Brian Hoffmann, President of West-Ward, said, "We are very pleased to be entering into a partnership with Granules Pharmaceuticals, Inc., adding this important oxytocic agent to our product portfolio in the US."